Elcelyx Therapeutics, developing a long-acting formulation of the old diabetes treatment metformin, closed a $40 million funding round to advance its lead therapy toward pivotal trials.
Neil Woodford's Patient Capital Trust has blessed the British-American biotech hybrid AMO Pharma with a $25 million investment to help fund development of a small pipeline of therapies for rare genetic disorders.
Corvus Pharmaceuticals, led by some former Pharmacyclics executives, banked a $75 million B round to support its work on an oral treatment that uses the body's natural defenses to combat cancer.
Accelerator, digging into the New York biotech scene, added another $11.7 million in new investments to its fourth fund, totaling $62.8 million earmarked for bets in life sciences.
Three years ago, after Merck Serono pulled the plug on its operations in Switzerland, a team of 8 neurodegeneration specialists used the shutdown as an opportunity to start their own biotech spinout, dubbed Asceneuron. And now they've gathered a substantial $30.6 million round to fund their drive into the clinic with a new drug candidate for Alzheimer's disease.
A little more than a year after Deciphera CEO Mike Taylor set up an office for the biotech in the Boston area, the cancer drug developer has rounded up a whopping $75 million B round to make a clinical push for its top cancer drug candidates.
Intarcia Therapeutics is rolling toward an FDA application with its long-acting diabetes treatment, but despite the ready availability of IPO cash for drug developers, the company is content to stay private for now.
The biotech IPO window is still wide open and ready for new business, especially if it relates to a hot new tech like gene therapy. RegenX Bio proved that point today, raising $138 million from the sale of 6.3 million shares at $22 a pop.
Less than two years after OrbiMed unleashed its last big biotech fund, the venture group is going back to the well to piece together an even bigger, $950 million cache of cash.
Third Rock Ventures startup Nurix is lending its drug-development prowess to Celgene in exchange for $150 million up front and much more down the line, collaborating on potential treatments for cancer and immunology.